To the full analysis
Corcept Therapeutics stock: growth
CORTCorcept Therapeutics reported $761.41M in revenue for fiscal 2025, up 12.8% on the prior year, up 16.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
51.2%
per year from 2006 to 2025, per share 39.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 16.6% | 31.2% | 51.2% |
| Revenue per share | 19.0% | 31.6% | 39.6% |
| Earnings | −1.2% | no data | no data |
| Earnings per share | 0.6% | no data | no data |
| Free cash flow | −1.2% | 46.5% | no data |
| Free cash flow per share | 0.9% | 46.9% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $294K | −$24.87M | −$24.55M |
| 2007 | $482K | −$11.57M | −$10.96M |
| 2008 | $209K | −$20.06M | −$18.37M |
| 2009 | $29K | −$20.17M | −$17.98M |
| 2010 | $0 | −$25.97M | −$22.29M |
| 2011 | $0 | −$32.35M | −$27.43M |
| 2012 | $3.31M | −$38.05M | −$36.17M |
| 2013 | $10.36M | −$46.01M | −$37.19M |
| 2014 | $26.55M | −$31.38M | −$27.55M |
| 2015 | $50.29M | −$6.41M | $3.11M |
| 2016 | $81.32M | $8.14M | $18.2M |
| 2017 | $159.2M | $129.12M | $60.52M |
| 2018 | $251.25M | $75.41M | $115.37M |
| 2019 | $306.49M | $94.18M | $135.03M |
| 2020 | $353.87M | $106.01M | $150.73M |
| 2021 | $365.98M | $112.51M | $167.42M |
| 2022 | $401.86M | $101.42M | $119.91M |
| 2023 | $482.38M | $106.14M | $126.9M |
| 2024 | $675.04M | $139.73M | $195.9M |
| 2025 | $761.41M | $99.65M | $141.79M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.